oxybutynin has been researched along with Pain, Chronic in 45 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effectiveness and tolerability of transdermal buprenorphine (TDB) treatment in real-world setting in Asian patients with musculoskeletal pain." | 9.24 | Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. ( Bin, SI; Chan, SK; Chung, CK; In, Y; Kim, H; Lichauco, JJ; Mok, CC; Moon, H; Moon, YW; Ng, TK; Penserga, EG; Shin, DA; Yoon, DH; You, D, 2017) |
| "This study examines the efficacy of the buprenorphine transdermal system (BTDS) for reducing the interference of pain on physical and emotional functioning associated with chronic low back pain (CLBP)." | 9.20 | Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. ( Lynch, SY; Miller, K; Munera, C; Pergolizzi, JV; Raffa, R; Ripa, SR; Wen, W; Yarlas, A, 2015) |
| "To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health-related quality of life (HRQoL) for patients with chronic low back pain (CLBP), and the maintenance of effects over 52 weeks." | 9.17 | Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. ( Brennan, MJ; Dain, B; Lynch, SY; Miller, K; Ripa, SR; Wen, W; Yarlas, A, 2013) |
| "The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients." | 9.16 | Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. ( Apkarian, AV; Baliki, MN; Chanda, ML; Hashmi, JA; Huang, L; Parks, EL; Schnitzer, T, 2012) |
| "In this enriched design study, 1,160 opioid-experienced patients with chronic, moderate to severe low back pain entered an open-label run-in period; 660 demonstrated analgesic benefit from and tolerability to buprenorphine transdermal system 20 mcg/hour (BTDS 20) treatment and were randomized to receive either BTDS 20, BTDS 5 mcg/hour (BTDS 5), or the active control (immediate release oxycodone 40-mg/day) during an 84-day double-blind phase." | 9.15 | Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. ( Hale, M; Landau, C; Munera, C; Ripa, S; Steiner, D, 2011) |
| "Local anesthetics, such as the 5% transdermal lidocaine patch (5LP), have been frequently used in the treatment of musculoskeletal pain, especially chronic low back pain (CLBP)." | 9.05 | The Efficacy, Effectiveness and Safety of 5% Transdermal Lidocaine Patch for Chronic Low Back Pain: A Narrative Review. ( Felix, ER; Klass, S; Santana, JA, 2020) |
| " Results from a network meta-analysis of non-enriched designs (eight trials), using trials versus placebo and trials versus morphine for indirect comparisons, indicated that transdermal fentanyl, in comparison with transdermal buprenorphine, showed significantly more nausea (odds ratio [OR] 4." | 8.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| "Efficacy and tolerability of buprenorphine patches was demonstrated in chronic pain patients, regardless of age, supporting the conclusion that no age-related dose adjustment of transdermal buprenorphine is needed." | 7.80 | Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. ( Augustini, BG; Berggren, AC; Karlsson, J; Söderström, A, 2014) |
| " The use of transdermal buprenorphine for chronic pain management is discussed." | 7.79 | Buprenorphine for chronic pain. ( Calderon, R; Copenhaver, D, 2013) |
| "Six-months analysis of non-interventionally collected observation data of effectiveness of long-term treatment with low-dose 7-day buprenorphine transdermal patch in elderly patients with chronic pain." | 7.79 | [Long-term treatment of chronic pain with low-dose 7-day buprenorphine transdermal patch. Observational data from elderly patients of pain relief and quality of life]. ( Müller-Schwefe, GH; Uberall, MA, 2013) |
| "Treatment of chronic pain conditions is commonly assessed at specific endpoints at preset times during or after treatment by analysis of the total study population." | 6.78 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. ( Dahan, A; Krebs-Brown, A; Martini, CH; Olofsen, E; Passier, P; Stoker, M; Yassen, A, 2013) |
| "Background and aims Chronic pain is a life altering condition and common among elderly persons." | 5.42 | Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights. ( Dahm, P; Norrlid, H; Tennvall, GR, 2015) |
| "We examined the effectiveness and tolerability of transdermal buprenorphine (TDB) treatment in real-world setting in Asian patients with musculoskeletal pain." | 5.24 | Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. ( Bin, SI; Chan, SK; Chung, CK; In, Y; Kim, H; Lichauco, JJ; Mok, CC; Moon, H; Moon, YW; Ng, TK; Penserga, EG; Shin, DA; Yoon, DH; You, D, 2017) |
| "This study examines the efficacy of the buprenorphine transdermal system (BTDS) for reducing the interference of pain on physical and emotional functioning associated with chronic low back pain (CLBP)." | 5.20 | Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. ( Lynch, SY; Miller, K; Munera, C; Pergolizzi, JV; Raffa, R; Ripa, SR; Wen, W; Yarlas, A, 2015) |
| "To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health-related quality of life (HRQoL) for patients with chronic low back pain (CLBP), and the maintenance of effects over 52 weeks." | 5.17 | Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. ( Brennan, MJ; Dain, B; Lynch, SY; Miller, K; Ripa, SR; Wen, W; Yarlas, A, 2013) |
| "The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients." | 5.16 | Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. ( Apkarian, AV; Baliki, MN; Chanda, ML; Hashmi, JA; Huang, L; Parks, EL; Schnitzer, T, 2012) |
| "In this enriched design study, 1,160 opioid-experienced patients with chronic, moderate to severe low back pain entered an open-label run-in period; 660 demonstrated analgesic benefit from and tolerability to buprenorphine transdermal system 20 mcg/hour (BTDS 20) treatment and were randomized to receive either BTDS 20, BTDS 5 mcg/hour (BTDS 5), or the active control (immediate release oxycodone 40-mg/day) during an 84-day double-blind phase." | 5.15 | Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. ( Hale, M; Landau, C; Munera, C; Ripa, S; Steiner, D, 2011) |
| "Local anesthetics, such as the 5% transdermal lidocaine patch (5LP), have been frequently used in the treatment of musculoskeletal pain, especially chronic low back pain (CLBP)." | 5.05 | The Efficacy, Effectiveness and Safety of 5% Transdermal Lidocaine Patch for Chronic Low Back Pain: A Narrative Review. ( Felix, ER; Klass, S; Santana, JA, 2020) |
| "Buprenorphine is a lipid-soluble pharmaceutic used in the management of chronic pain." | 4.91 | Buprenorphine: revisiting the efficacy of transdermal delivery system. ( Barnett, CJ; Bergese, SD; Kamar, N; Kitzmiller, JP; Luzum, JA; Mikulik, E; Steiner, NS; Stoicea, N, 2015) |
| " Results from a network meta-analysis of non-enriched designs (eight trials), using trials versus placebo and trials versus morphine for indirect comparisons, indicated that transdermal fentanyl, in comparison with transdermal buprenorphine, showed significantly more nausea (odds ratio [OR] 4." | 4.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| "Buprenorphine is a partial mu-opioid agonist available as a transdermal patch for use in patients with chronic pain." | 4.12 | Application Site Reactions from the Buprenorphine Transdermal Patch: A Case Series. ( Fudin, J; Mendoza, K; Meyer-Junco, L; Rea, B, 2022) |
| " This study compares rates of poison center calls categorized as intentional abuse, suspected suicidal intent or fatality for the 7-day buprenorphine transdermal system/patch (BTDS) with other extended-release and long-acting (ER/LA) opioids indicated for chronic pain." | 3.85 | Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System. ( Coplan, PM; Harikrishnan, V; Perkel, C; Sessler, NE; Singh, R, 2017) |
| "Efficacy and tolerability of buprenorphine patches was demonstrated in chronic pain patients, regardless of age, supporting the conclusion that no age-related dose adjustment of transdermal buprenorphine is needed." | 3.80 | Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. ( Augustini, BG; Berggren, AC; Karlsson, J; Söderström, A, 2014) |
| "To characterize the profile of application site reactions (ASRs) for patients treated with the buprenorphine transdermal system (BTDS) in chronic pain studies." | 3.79 | Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis. ( Lynch, SY; Maibach, H; Munera, C; Ripa, SR; Swanton, R; Wen, W, 2013) |
| " The use of transdermal buprenorphine for chronic pain management is discussed." | 3.79 | Buprenorphine for chronic pain. ( Calderon, R; Copenhaver, D, 2013) |
| "Six-months analysis of non-interventionally collected observation data of effectiveness of long-term treatment with low-dose 7-day buprenorphine transdermal patch in elderly patients with chronic pain." | 3.79 | [Long-term treatment of chronic pain with low-dose 7-day buprenorphine transdermal patch. Observational data from elderly patients of pain relief and quality of life]. ( Müller-Schwefe, GH; Uberall, MA, 2013) |
| "Treatment of chronic pain conditions is commonly assessed at specific endpoints at preset times during or after treatment by analysis of the total study population." | 2.78 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. ( Dahan, A; Krebs-Brown, A; Martini, CH; Olofsen, E; Passier, P; Stoker, M; Yassen, A, 2013) |
| " Various retrospective studies comparing dosage changes of buprenorphine and fentanyl patches in persistent pain patients have been completed; however, no long-term prospective, randomized, clinical study has compared the effectiveness of these patches." | 2.78 | A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. ( Chowdhury, S; Mitra, F; Shelley, M; Williams, G, 2013) |
| "Many patients experience acute or chronic pain." | 2.52 | [Certain opioids can preferably be administered transdermally]. ( Holmgaard, R; Jensen, NM; Nielsen, JB; Sørensen, JA, 2015) |
| "Neuropathic pain is a complex condition that is difficult to control and has a high impact on quality of life." | 1.56 | 8% Capsaicin Patch in Treatment of Peripheral Neuropathic Pain. ( Barbosa, P; Gomes, A; Goncalves, D; Rebelo, V, 2020) |
| "Tramadol has a higher risk of fractures than some other opioid analgesics used to treat moderate-to-severe pain and, in the model described here, we investigate the cost effectiveness of transdermal buprenorphine treatment compared with tramadol in a high-risk population." | 1.43 | Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine. ( Akehurst, R; Dunlop, W; Hirst, A; Hirst, M; Knight, C, 2016) |
| "Background and aims Chronic pain is a life altering condition and common among elderly persons." | 1.42 | Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights. ( Dahm, P; Norrlid, H; Tennvall, GR, 2015) |
| " Initial BTDS dosing strength, receipt of approved initial BTDS dose per the FPI, and concomitant medications were assessed in the post-index 6 month period." | 1.40 | US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system. ( Ben-Joseph, R; Chang, CL; Hess, G; Pergolizzi, JV, 2014) |
| "Buprenorphine is a chemically synthesized opioid characterized as the partial mu agonist and kappa antagonist, and transdermal buprenorphine patch will be considered useful as a strong analgesic with fewer psychological side effects in the treatment of chronic non-cancer pain." | 1.39 | [Buprenorphine transdermal patch (Norspan tape)]. ( Hamaguchi, S; Ikeda, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 41 (91.11) | 24.3611 |
| 2020's | 4 (8.89) | 2.80 |
| Authors | Studies |
|---|---|
| Kapoor, H | 1 |
| Gupta, E | 1 |
| Sood, A | 1 |
| Meyer-Junco, L | 1 |
| Rea, B | 1 |
| Mendoza, K | 1 |
| Fudin, J | 1 |
| Santana, JA | 1 |
| Klass, S | 1 |
| Felix, ER | 1 |
| Noe, MH | 1 |
| Shin, DB | 1 |
| Wehner, MR | 1 |
| Margolis, DJ | 1 |
| Gelfand, JM | 1 |
| Goncalves, D | 1 |
| Rebelo, V | 1 |
| Barbosa, P | 1 |
| Gomes, A | 1 |
| Yoon, DH | 1 |
| Bin, SI | 1 |
| Chan, SK | 1 |
| Chung, CK | 1 |
| In, Y | 1 |
| Kim, H | 1 |
| Lichauco, JJ | 1 |
| Mok, CC | 1 |
| Moon, YW | 1 |
| Ng, TK | 1 |
| Penserga, EG | 1 |
| Shin, DA | 1 |
| You, D | 1 |
| Moon, H | 1 |
| Norrlid, H | 1 |
| Dahm, P | 1 |
| Tennvall, GR | 1 |
| Chung, CP | 1 |
| Dupont, WD | 1 |
| Murray, KT | 1 |
| Hall, K | 1 |
| Stein, CM | 1 |
| Ray, WA | 1 |
| Davis, MP | 1 |
| Pasternak, G | 1 |
| Behm, B | 1 |
| Luchting, B | 1 |
| Azad, SC | 1 |
| Taylor, RG | 1 |
| Budhram, A | 1 |
| Lee, DH | 1 |
| Mirsattari, SM | 1 |
| Wen, W | 3 |
| Lynch, SY | 3 |
| Munera, C | 3 |
| Swanton, R | 1 |
| Ripa, SR | 3 |
| Maibach, H | 1 |
| Martini, CH | 1 |
| Yassen, A | 1 |
| Krebs-Brown, A | 1 |
| Passier, P | 1 |
| Stoker, M | 1 |
| Olofsen, E | 1 |
| Dahan, A | 1 |
| Ibuki, T | 1 |
| Hamaguchi, S | 1 |
| Ikeda, T | 1 |
| Collopy, KT | 1 |
| Kivlehan, SM | 1 |
| Snyder, SR | 1 |
| Weekes, G | 1 |
| O'Brien, J | 1 |
| Murphy, K | 1 |
| Keavney, J | 1 |
| Pollard, V | 1 |
| Chapman, CR | 1 |
| Bradshaw, DH | 1 |
| Calderon, R | 1 |
| Copenhaver, D | 1 |
| Karlsson, J | 1 |
| Söderström, A | 1 |
| Augustini, BG | 1 |
| Berggren, AC | 1 |
| Pergolizzi, JV | 3 |
| Ben-Joseph, R | 2 |
| Chang, CL | 2 |
| Hess, G | 2 |
| Uberall, MA | 1 |
| Müller-Schwefe, GH | 1 |
| López-Pérez, FJ | 1 |
| Mínguez-Martí, A | 1 |
| Vicario-Sánchez, E | 1 |
| Pastor-Clérigues, A | 1 |
| Sanfeliu-García, J | 1 |
| Ortega-García, MP | 1 |
| Dankiewicz, EH | 1 |
| Haddox, JD | 1 |
| Yarlas, A | 2 |
| Miller, K | 2 |
| Raffa, R | 1 |
| Jensen, NM | 1 |
| Holmgaard, R | 1 |
| Nielsen, JB | 1 |
| Sørensen, JA | 1 |
| Hirst, A | 1 |
| Knight, C | 1 |
| Hirst, M | 1 |
| Dunlop, W | 1 |
| Akehurst, R | 1 |
| Kitzmiller, JP | 1 |
| Barnett, CJ | 1 |
| Steiner, NS | 1 |
| Stoicea, N | 1 |
| Kamar, N | 1 |
| Luzum, JA | 1 |
| Mikulik, E | 1 |
| Bergese, SD | 1 |
| Rascol, O | 1 |
| Zesiewicz, T | 1 |
| Chaudhuri, KR | 1 |
| Asgharnejad, M | 1 |
| Surmann, E | 1 |
| Dohin, E | 1 |
| Nilius, S | 1 |
| Bauer, L | 1 |
| Oppliger, M | 1 |
| Mauermann, E | 1 |
| Ruppen, W | 1 |
| Kawai, K | 1 |
| Yoshizawa, K | 1 |
| Fujie, M | 1 |
| Kobayashi, H | 1 |
| Ogawa, Y | 1 |
| Yajima, T | 1 |
| Romualdi, P | 1 |
| Santi, P | 1 |
| Candeletti, S | 1 |
| Coplan, PM | 1 |
| Sessler, NE | 1 |
| Harikrishnan, V | 1 |
| Singh, R | 1 |
| Perkel, C | 1 |
| Trist, AJ | 1 |
| Sahota, H | 1 |
| Williams, L | 1 |
| Steiner, D | 1 |
| Hale, M | 1 |
| Ripa, S | 1 |
| Landau, C | 1 |
| Rastogi, R | 1 |
| Swarm, RA | 1 |
| Patel, TA | 1 |
| Plosker, GL | 1 |
| Lyseng-Williamson, KA | 1 |
| Wolff, RF | 1 |
| Aune, D | 1 |
| Truyers, C | 1 |
| Hernandez, AV | 1 |
| Misso, K | 1 |
| Riemsma, R | 1 |
| Kleijnen, J | 1 |
| Hashmi, JA | 1 |
| Baliki, MN | 1 |
| Huang, L | 1 |
| Parks, EL | 1 |
| Chanda, ML | 1 |
| Schnitzer, T | 1 |
| Apkarian, AV | 1 |
| Miotto, K | 1 |
| Kaufman, A | 1 |
| Kong, A | 1 |
| Jun, G | 1 |
| Schwartz, J | 1 |
| Steunebrink, M | 1 |
| Zwerver, J | 1 |
| Brandsema, R | 1 |
| Groenenboom, P | 1 |
| van den Akker-Scheek, I | 1 |
| Weir, A | 1 |
| López Ramírez, E | 1 |
| Mitra, F | 1 |
| Chowdhury, S | 1 |
| Shelley, M | 1 |
| Williams, G | 1 |
| Dain, B | 1 |
| Brennan, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid [NCT01961271] | Phase 4 | 114 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [NCT01276431] | Phase 4 | 102 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-release Versus BTDS 5 in Subjects With Moderate to Severe Low Back Pain[NCT00313014] | Phase 3 | 660 participants (Actual) | Interventional | 2004-02-29 | Terminated (stopped due to Terminated early due to administrative reasons unrelated to efficacy or safety.) | ||
| Mind-body Treatments for Chronic Back Pain[NCT03294148] | 151 participants (Actual) | Interventional | 2017-08-07 | Completed | |||
| Randomized, Placebo-controlled Crossover Trial Evaluating Topical Lidocaine Patch(es) for Mechanical Neck Pain.[NCT04378959] | 76 participants (Actual) | Interventional | 2021-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary efficacy outcome analysis is the pre- and post-intervention change in BS-11 pain score. The reduction in scores were calculated by subtracting the post-intervention score from the baseline score.~BS-11 is known as Box scale-11; it is an 11-point scale measuring pain intensity. It ranges from 0 to 10, whereby 0 represents no pain and 10 represents the worst imaginable pain. Subjects selected a number based on the pain intensity they were feeling at that time." (NCT01961271)
Timeframe: Maximum 17 weeks starting from enrolment
| Intervention | units on a scale (Mean) |
|---|---|
| Buprenorphine Transdermal Patch | 2.7 |
(NCT01961271)
Timeframe: From time of enrolment to Visit 6 (ie. up to119 days from enrolment)
| Intervention | participants (Number) |
|---|---|
| Buprenorphine Transdermal Patch | 3 |
Daily use of breakthrough pain medication from visits 1-6, assessed from patient diaries. (NCT01961271)
Timeframe: Approximately 17 weeks starting from enrolment
| Intervention | participants (Number) |
|---|---|
| Buprenorphine Transdermal Patch | 26 |
Side effects of the transdermal patch treatment will be analysed. (NCT01961271)
Timeframe: From time of enrolment up to 7 days after completion / discontinuation visit (up to 140 days)
| Intervention | participants (Number) |
|---|---|
| Buprenorphine Transdermal Patch | 89 |
"Pre-intervention: Visit 1 Post-intervention: Visit 6~There are 5 dimensions in the EQ5D-3L questionnaire answered by the subjects, classified into 5 categories here:~Mobility -- change in % of subjects who have no problem in walking around Self-care -- change in % of subjects who have no problem in self-care Usual activities -- change in % of subjects who have no problem with performing their usual activities Pain/ discomfort -- change in % of subjects who do not experience pain or discomfort Anxiety/ depression -- change in % of subjects who do not feel anxious or depressed" (NCT01961271)
Timeframe: approximately 17 weeks starting from enrolment
| Intervention | percentage of subjects (Number) | ||||
|---|---|---|---|---|---|
| Mobility | Self-care | Usual Activities | Pain/Discomfort | Anxiety/ Depression | |
| Buprenorphine Transdermal Patch | 25.8 | 20.2 | 19.4 | 14.3 | 18 |
"The overall assessment of the change in pain intensity from baseline is measured at Visit 6.~Physician's Global Impression of Change scale: Investigator's opinion on a scale of 1 to 7 where 1 is very much improved and 7 is very much worse Patient's Global Impression of Change scale: Subject's opinion on a scale of 1 to 7 where 1 is very much improved and 7 is very much worse" (NCT01961271)
Timeframe: At visit 6 (anywhere between Day 91 to 119 after enrolment depending on how long titration took)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Physician Impression | Patient Impression | |
| Buprenorphine Transdermal Patch | 2.62 | 2.66 |
The mean daily number of tablets of supplemental analgesic medications used during the double-blind phase (NCT00313014)
Timeframe: Double-blind phase (84 days)
| Intervention | tablets (Mean) |
|---|---|
| Double-blind BTDS 5 | 3.8 |
| Double-blind BTDS 20 | 3.3 |
| Double-blind Oxycodone Immediate-Release | 3.5 |
"Subjects were evaluated during the double-blind phase for average pain over the last 24 hours prior to the study visits. Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine)" (NCT00313014)
Timeframe: Last 24 hours score at weeks 4, 8, 12 of the double-blind phase
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Screening | Prerandomization | Week 4 | Week 8 | Week 12 | |
| Double-blind BTDS 20 | 6.46 | 2.91 | 3.40 | 3.35 | 3.35 |
| Double-blind BTDS 5 | 6.36 | 2.84 | 3.79 | 3.83 | 4.02 |
| Double-blind Oxycodone Immediate-Release | 6.46 | 2.74 | 3.14 | 3.24 | 3.26 |
"The ODI (version 2) is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes.~The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0 = good to 5 = worse). (Note: A higher score represents greater disability.)" (NCT00313014)
Timeframe: Weeks 4, 8, 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Week 4 | Week 8 | Week 12 | |
| Double-blind BTDS 20 | 33.04 | 34.27 | 33.06 |
| Double-blind BTDS 5 | 34.80 | 35.69 | 36.30 |
| Double-blind Oxycodone Immediate-Release | 30.79 | 31.64 | 32.96 |
"The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity/ optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath).~Question 1 is scored on a scale of 1 to 5 and Questions 3 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance." (NCT00313014)
Timeframe: Weeks 4, 8, 12 of the double-blind phase
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Week 4 | Week 8 | Week 12 | |
| Double-blind BTDS 20 | 34.65 | 35.69 | 33.65 |
| Double-blind BTDS 5 | 40.67 | 42.28 | 40.85 |
| Double-blind Oxycodone Immediate-Release | 38.10 | 39.17 | 41.60 |
1-week average pain intensity, 0 - 10 numerical rating scale, where a higher score indicates more pain. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 1.18 |
| Placebo | 2.84 |
| Usual Care | 3.13 |
Questionnaire to rate negative affect, scores range from 5 - 25, with a higher score meaning a stronger negative affect (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 8.30 |
| Placebo | 7.70 |
| Usual Care | 8.19 |
Back pain disability questionnaire measured on a scale of 0-100. A higher score indicates a higher severity of disability. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 10.14 |
| Placebo | 19.00 |
| Usual Care | 20.68 |
Questionnaire used to help quantify an individual's pain experience. Measured 0-52. A higher score means a higher level of catastrophizing. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 8.30 |
| Placebo | 7.70 |
| Usual Care | 8.19 |
Post-treatment-only outcome measure depicting a patient's subjective rating of overall improvement. Score ranges from 1-7 with a higher score indicating a higher level of change and improvement (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 6.14 |
| Placebo | 3.61 |
| Usual Care | 2.06 |
Questionnaire to rate positive affect, scores range from 5 - 25, a higher score means stronger affect (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 17.89 |
| Placebo | 15.20 |
| Usual Care | 14.98 |
Questionnaire measuring anger (5 items) with a score range of 5-25. Higher scores indicate a higher severity of anger. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 9.52 |
| Placebo | 9.89 |
| Usual Care | 10.45 |
Questionnaire measuring anxiety (8 items). Scores range from 8-40 with a higher score meaning more severe levels of fear, anxious misery, hyperarousal, and somatic symptoms related to arousal. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 15.02 |
| Placebo | 13.89 |
| Usual Care | 14.11 |
Questionnaire measuring sleep disturbance (8 items). Scores range from 8-40. Higher scores indicate higher levels of sleep disturbance (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 17.73 |
| Placebo | 20.50 |
| Usual Care | 20.89 |
Questionnaire measuring depression (8 items). Scores range from 8-32. A higher score indicates higher levels of depressive symptoms (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 12.23 |
| Placebo | 11.75 |
| Usual Care | 11.81 |
Questionnaire used to assess the subjective rating of kinesiophobia or fear of movement. Scores range from 11-44 with higher scores indicating greater fear of pain, movement, and injury. (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 16.41 |
| Placebo | 22.16 |
| Usual Care | 22.51 |
Questionnaire used to assess daily drinking (number of drinks consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | Drinks (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 11.63 |
| Placebo | 12.88 |
| Usual Care | 8.02 |
Questionnaire used to assess daily cannabis use (number of grams consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | Grams of cannabis (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 6.76 |
| Placebo | 3.31 |
| Usual Care | 1.49 |
Questionnaire used to assess daily opioid use (number of pills consumed over past two weeks) (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | Opioid pills (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 1.29 |
| Placebo | 0.36 |
| Usual Care | 1.77 |
Post-treatment-only outcome measure depicting the patient's satisfaction with the treatment. Measured 0 - 100. A higher score means higher satisfaction with treatment/ (NCT03294148)
Timeframe: At post-treatment fMRI session, approximately 1 month after randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Pain Reprocessing Therapy (PRT) | 92.40 |
| Placebo | 57.61 |
| Usual Care | 36.86 |
10 reviews available for oxybutynin and Pain, Chronic
| Article | Year |
|---|---|
Chronic pelvic ischemia: etiology, pathogenesis, clinical presentation and management.
Topics: Aged; Animals; Atherosclerosis; Calcium; Cell Hypoxia; Chronic Pain; Disease Models, Animal; Estroge | 2014 |
The Efficacy, Effectiveness and Safety of 5% Transdermal Lidocaine Patch for Chronic Low Back Pain: A Narrative Review.
Topics: Anesthetics, Local; Chronic Pain; Humans; Lidocaine; Low Back Pain; Randomized Controlled Trials as | 2020 |
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.
Topics: Administration, Sublingual; Analgesics, Opioid; Animals; Buprenorphine; Chemistry, Pharmaceutical; C | 2018 |
Pain therapy for the elderly patient: is opioid-free an option?
Topics: Administration, Topical; Age Factors; Aged; Aging; Analgesics, Non-Narcotic; Analgesics, Opioid; Cap | 2019 |
[Certain opioids can preferably be administered transdermally].
Topics: Acute Pain; Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Anti-Inflammatory A | 2015 |
Buprenorphine: revisiting the efficacy of transdermal delivery system.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Drug Delivery Systems; Humans; Transdermal Patch | 2015 |
Alghedon Fentanyl Transdermal System.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Pain; Delayed-Action Preparations; Fentanyl; | 2017 |
Case scenario: opioid association with serotonin syndrome: implications to the practitioners.
Topics: Analgesics, Opioid; Antidepressive Agents, Tricyclic; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhi | 2011 |
Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Delayed-Action Preparations; Dose-Response Relation | 2012 |
Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Chronic Pain; Constipation; Fentanyl; Human | 2012 |
9 trials available for oxybutynin and Pain, Chronic
| Article | Year |
|---|---|
Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Hon | 2017 |
A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia.
Topics: Aged; Aged, 80 and over; Capsaicin; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Ma | 2013 |
Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Double-Blind Meth | 2015 |
A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
Topics: Aged; Chronic Pain; Dopamine Agonists; Double-Blind Method; Female; Humans; Internationality; Male; | 2016 |
Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Chronic Pain; Double-Blind Method; Fem | 2011 |
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study.
Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne | 2012 |
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study.
Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne | 2012 |
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study.
Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne | 2012 |
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study.
Topics: Back Pain; Brain; Brain Mapping; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Magne | 2012 |
Topical glyceryl trinitrate treatment of chronic patellar tendinopathy: a randomised, double-blind, placebo-controlled clinical trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics; Chronic Pain; Double-Blind Method; Humans; | 2013 |
A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Disease; Chronic Pain; | 2013 |
Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Dose-Response Rel | 2013 |
26 other studies available for oxybutynin and Pain, Chronic
| Article | Year |
|---|---|
Application Site Reactions from the Buprenorphine Transdermal Patch: A Case Series.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Transdermal Patc | 2022 |
Opioid prescribing in adults with and without psoriasis.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Chronic Pain; Dermatologic Agents; Drug Presc | 2020 |
8% Capsaicin Patch in Treatment of Peripheral Neuropathic Pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Capsaicin; Child; Chronic Pain; Female; Humans; Male; Mi | 2020 |
Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chronic Pain; Clinical Trials as Topic; | 2015 |
Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Delayed-Action Preparations; Drug Overdose; Female; F | 2019 |
Opioid-associated amnestic syndrome observed with fentanyl patch use.
Topics: Administration, Cutaneous; Amnesia; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Humans; Midd | 2019 |
Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis.
Topics: Administration, Cutaneous; Aged; Buprenorphine; Chronic Pain; Clinical Trials, Phase III as Topic; D | 2013 |
[Transdermal fentanyl patch for the treatment of chronic intractable pain].
Topics: Analgesics, Opioid; Chronic Pain; Fentanyl; Humans; Pain, Intractable; Transdermal Patch | 2013 |
[Buprenorphine transdermal patch (Norspan tape)].
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Pain, Intractable; Transdermal Patch | 2013 |
An EMS guide to chronic pain.
Topics: Analgesics, Opioid; Anticonvulsants; Biological Availability; Chronic Pain; Drug Therapy, Combinatio | 2013 |
Qutenza patch--our early experience.
Topics: Activities of Daily Living; Analgesics; Capsaicin; Chronic Pain; Humans; Neuralgia; Pain Measurement | 2013 |
Only modest long-term opioid dose escalation occurs over time in chronic nonmalignant pain management.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Pain; | 2013 |
Buprenorphine for chronic pain.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Opiate Substitution Treatment; Opioid-Relat | 2013 |
Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study.
Topics: Age Factors; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Human | 2014 |
Predicting medication persistence to buprenorphine transdermal system.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammat | 2015 |
US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chronic Pain; Databas | 2014 |
[Long-term treatment of chronic pain with low-dose 7-day buprenorphine transdermal patch. Observational data from elderly patients of pain relief and quality of life].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anxiety; Buprenorphine; Chronic Pain; Depressio | 2013 |
[Clinical experience in opioid switch for noncancer chronic pain treatment].
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Aged; Aged, 80 and over; Analgesia, Epidural; Analges | 2014 |
Clarification on transdermal buprenorphine.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Transdermal Patch | 2014 |
Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine.
Topics: Aged; Aged, 80 and over; Buprenorphine; Chronic Pain; Cost-Benefit Analysis; Drug Costs; Female; Fra | 2016 |
Are transdermal opioids contraindicated in patients at risk of suicide?: An underappreciated problem.
Topics: Analgesics, Opioid; Autopsy; Chronic Pain; Death, Sudden, Cardiac; Female; Fentanyl; Humans; Middle | 2016 |
Use of Fentanyl Patch for Treatment of Moderate-to-severe Chronic Noncancer Pain: Postmarketing Surveillance of Medical Practice in Japan Using a Risk Minimization Action Plan.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Humans; Japan; Male; Middle Aged; O | 2017 |
Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Cause of Death; Chronic Pain; Coh | 2017 |
Not so patchy story of attempted suicide…leading to 24 hours of deep sleep and survival!
Topics: Aged; Analgesics, Opioid; Back Pain; Chronic Pain; Drug Overdose; Female; Fentanyl; Humans; Suicide, | 2017 |
Managing co-occurring substance use and pain disorders.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Child; Chronic Pain; Diagnostic and | 2012 |
Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience.
Topics: Acute Pain; Aged; Aged, 80 and over; Anesthetics, Local; Chronic Pain; Female; Humans; Lidocaine; Ma | 2013 |